摘要
Abstract
Objective:To investigate the clinical efficacy of Zishen Hugan formula in the treatment of patients with premature ovarian failure and liver-kidney yin deficiency syndrome.Methods:A total of 90 patients with premature ovarian failure and liver-kidney yin deficiency syndrome treated in a hospital from October 2020 to October 2022 were selected prospectively and assigned to the control group and the observation group by random number table method,with 45 patients in each group.The control group was treated with complex packing estradiol tablets/estradiol and dydrogesterone tablets,and the observation group was treated with Zishen Hugan formula.Both groups were treated for 3 courses.The levels of sex hormones[follicle-stimulating hormone(FSH),luteinizing hormone(LH),estradiol(E2)],clinical efficacy,adverse reactions and disease recurrence after 6-month follow-up were compared between the two groups.Results:After 3 courses of treatment,the levels of serum FSH and LH were decreased in both groups(P<0.05),with the observation group showing lower levels than the control group(P<0.05).The serum E2 level was increased in both groups(P<0.05),with the observation group showing higher levels than the control group(P<0.05).The total effective rate in the observation group(95.56%)was higher than that in the control group(80.00%,P<0.05).The total incidence of adverse reactions in the observation group(4.44%)was lower than that in the control group(17.78%,χ2=4.050,P=0.044).After 6-month follow-up,the recurrence rate in the observation group(2.22%)was lower than that in the control group(17.78%,χ2=4.444,P=0.035).Conclusion:Zishen Hugan formula can improve the clinical efficacy in patients with premature ovarian failure and liver-kidney yin deficiency syndrome,improving estrogen levels,with fewer adverse reactions and a lower recurrence rate.关键词
卵巢早衰/肝肾阴虚证/滋肾护肝方/雌激素/临床疗效/性激素Key words
premature ovarian failure/liver-kidney yin deficiency syndrome/Zishen Hugan formula/estrogen/clinical efficacy/sex hormone分类
医药卫生
